quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 13, 2026

Billionaire Investor Quietly Loads Up On Construction Stocks As One Gets The Axe

View original at finance.yahoo.com
“Also, APi priced a private offering of $500 million in 5.75% senior unsecured notes due 2034.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • APi Group Q1 2026 EPS was $0.32, beating analyst estimates of $0.30 and rising 28% year over year

    60% confidence
  • MasTec sees full-year FY26 revenue of about $17.5 billion, above Wall Street expectations of $17.04 billion

    60% confidence
  • Goldman Sachs raised its MasTec forecast from $348 to $487

    60% confidence
  • APi Group forecasts Q2 2026 revenue of $2.18B–$2.23B, above the consensus estimate of $2.16B

    60% confidence
  • MasTec raised its FY26 adjusted EPS guidance from $8.40 to $8.79, above the analyst consensus of $8.51

    60% confidence
  • APi Group priced a private offering of $500M in 5.75% senior unsecured notes due 2034, with proceeds primarily funding acquisitions of Onyx-Fire Protection Services and Wtech Fire Group

    60% confidence
  • MasTec Q1 2026 EPS was $1.39, surpassing analyst estimates of $0.99 and rising sharply from $0.51 a year earlier

    60% confidence
  • MasTec expects Q2 2026 adjusted EPS of $2.20, above analyst projections of $2.12

    60% confidence
  • UBS raised its APi Group price forecast from $54 to $56

    60% confidence
  • APi Group raised its FY2026 revenue guidance to $8.48B–$8.68B from the prior range of $8.40B–$8.60B, versus analyst estimates of $8.53B

    60% confidence
  • Truist Financial raised its MasTec forecast from $425 to $518

    60% confidence
  • APi Group Q1 2026 revenue increased 15.3% YoY to $1.98 billion, ahead of the $1.92 billion consensus estimate

    60% confidence
  • Truist Securities raised its APi Group price forecast from $53 to $55

    60% confidence
  • MasTec anticipates Q2 2026 revenue of approximately $4.3 billion versus the $4.2 billion consensus estimate

    60% confidence
  • TD Cowen raised its MasTec estimate from $320 to $445

    60% confidence
  • MasTec Q1 2026 revenue climbed 34.5% YoY to $3.83 billion, ahead of the $3.49 billion consensus estimate

    60% confidence
  • Robert W. Baird raised its MasTec forecast from $348 to $473

    60% confidence
  • Mizuho raised its MasTec price forecast from $428 to $498

    60% confidence
  • Barclays raised its APi Group price forecast from $52 to $54

    60% confidence
  • Citigroup raised its MasTec forecast from $440 to $483

    60% confidence

Data points we hold from this source

Barclays · analyst price target54 USD
UBS Group AG · analyst price target56 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Billionaire Investor Quietly Loads Up On Construction Stocks As One Gets The Axe — Source | Via News | pt.VIA.NEWS